Genomic’s Prostate Cancer Test Recommended by Palmetto
Genomic Health, Inc.(GHDX – Analyst Report) recently declared that Medicare contractor, Palmetto GBA, has issued a draft local coverage determination (LCD) for its Oncotype DX prostate cancer test. The draft LCD recommends coverage and reimbursement of the Oncotype DX prostate cancer test for applicable Medicare patients across the U.S. This should encourage the identification of…